TY - JOUR
T1 - A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
AU - Palomba, M. Lia
AU - Ghione, Paola
AU - Patel, Anik R.
AU - Nahas, Myrna
AU - Beygi, Sara
AU - Hatswell, Anthony J.
AU - Kanters, Steve
AU - Limbrick-Oldfield, Eve H.
AU - Wade, Sally W.
AU - Ray, Markqayne D.
AU - Owen, Jessica
AU - Neelapu, Sattva S.
AU - Gribben, John
AU - Radford, John
AU - Bobillo, Sabela
N1 - Funding Information:
This manuscript was funded by Kite, a Gilead Company. We thank the patients who participated in this study and their families, caregivers, and friends.
Publisher Copyright:
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Background: In the ZUMA-5 trial (Clinical trials identification: NCT03105336), axicabtagene ciloleucel (axi-cel; a chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients and clear superiority relative to the SCHOLAR-5 external control cohort. We update this comparison using the ZUMA-5 24-month data. Research design and methods: The SCHOLAR-5 cohort is comprised of r/r FL patients who initiated ≥3rd line of therapy after July 2014 and meeting ZUMA-5 eligibility criteria. Groups were balanced for patient characteristics through propensity scoring on prespecified prognostic factors using standardized mortality ratio (SMR) weighting. The overall response rate was compared using a weighted logistic regression. Time-to-event outcomes were evaluated using a Cox regression. Results: For SCHOLAR-5, the sum of weights for the 143 patients was 85 after SMR weighting, versus 86 patients in ZUMA-5. The median follow-up was 29.4 months and 25.4 months for ZUMA-5 and SCHOLAR-5, respectively. The hazard ratios for overall survival and progression-free survival were 0.52 (95% confidence interval (CI): 0.28–0.95) and 0.28 (95% CI: 0.17–0.45), favoring axi-cel. Conclusion: This updated analysis, using a longer minimum follow-up than a previously published analysis, shows that the improved efficacy of axi-cel, relative to available therapies, in r/r FL is durable.
AB - Background: In the ZUMA-5 trial (Clinical trials identification: NCT03105336), axicabtagene ciloleucel (axi-cel; a chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients and clear superiority relative to the SCHOLAR-5 external control cohort. We update this comparison using the ZUMA-5 24-month data. Research design and methods: The SCHOLAR-5 cohort is comprised of r/r FL patients who initiated ≥3rd line of therapy after July 2014 and meeting ZUMA-5 eligibility criteria. Groups were balanced for patient characteristics through propensity scoring on prespecified prognostic factors using standardized mortality ratio (SMR) weighting. The overall response rate was compared using a weighted logistic regression. Time-to-event outcomes were evaluated using a Cox regression. Results: For SCHOLAR-5, the sum of weights for the 143 patients was 85 after SMR weighting, versus 86 patients in ZUMA-5. The median follow-up was 29.4 months and 25.4 months for ZUMA-5 and SCHOLAR-5, respectively. The hazard ratios for overall survival and progression-free survival were 0.52 (95% confidence interval (CI): 0.28–0.95) and 0.28 (95% CI: 0.17–0.45), favoring axi-cel. Conclusion: This updated analysis, using a longer minimum follow-up than a previously published analysis, shows that the improved efficacy of axi-cel, relative to available therapies, in r/r FL is durable.
KW - Follicular lymphoma
KW - ZUMA-5
KW - axicabtagene ciloleucel
KW - comparative effectiveness
KW - propensity score analysis
UR - http://www.scopus.com/inward/record.url?scp=85148070756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148070756&partnerID=8YFLogxK
U2 - 10.1080/14737140.2023.2171994
DO - 10.1080/14737140.2023.2171994
M3 - Article
C2 - 36723678
AN - SCOPUS:85148070756
SN - 1473-7140
VL - 23
SP - 199
EP - 206
JO - Expert review of anticancer therapy
JF - Expert review of anticancer therapy
IS - 2
ER -